0001690080
false
0001690080
2023-10-12
2023-10-12
0001690080
ATNF:CommonStockParValue0.0001PerShareMember
2023-10-12
2023-10-12
0001690080
ATNF:WarrantsToPurchaseSharesOfCommonStockMember
2023-10-12
2023-10-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13
OR 15(d) OF THE
SECURITIES EXCHANGE ACT
OF 1934
Date of Report (Date of earliest
event reported): October 12, 2023
180 LIFE SCIENCES CORP.
(Exact Name of Registrant
as Specified in Charter)
Delaware |
|
001-38105 |
|
90-1890354 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
3000 El Camino Real, Bldg. 4, Suite 200
Palo Alto, CA |
|
94306 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone
number, including area code: (650) 507-0669
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) |
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
ATNF |
|
The NASDAQ Stock Market LLC |
Warrants to purchase shares of Common Stock |
|
ATNFW |
|
The NASDAQ Stock Market LLC |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
180 Life Sciences Corp. (“180
Life Sciences” or the “Company”), reports that on October 12, 2023, the Company received a formal written
scientific response from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) regarding a meeting that
was held on August 17, 2023 with the MHRA. 180 Life Sciences’ management and regulatory team met with the MHRA to propose a path
forward for approval of the Company’s use of adalimumab as an anti-TNF (tumor necrosis factor) therapy for the potential prevention
of the Dupuytren’s contracture disability.
In the response,
the MHRA (i) recognized the debilitating nature of the Dupuytren’s Contracture; (ii) agreed with the Company’s proposed primary
and secondary endpoints for a proposed Phase 3 clinical trial (Phase 3 study); (iii) agreed that a single Phase 3 study could be sufficient
to support a Marketing Authorization, if convincing evidence of efficacy and safety is observed; (iv) confirmed that the MHRA believes
that the results of the Company’s Phase 2b trial resulted in too much uncertainty to support a Conditional Marketing Authorization
(CMA), because of the small number of trial participants, and that the MHRA would require the results of a Phase 3 study to consider a
Marketing Authorisation; and (v) provided the Company guidance on the potential Phase 3 study, including that a treatment course consisting
of four injections administered at 3-monthly intervals is acceptable.
The Company is
also currently interacting with the U.S. Food and Drug Administration (FDA), and is ready to liaise with the European Medicines Agency
(EMA), to attempt to obtain agreement on 180 Life Science’s proposed clinical development plans, as outlined above for the MHRA
guidance, and to work towards seeking approval of the use of adalimumab as an anti-TNF therapy for potential prevention of the Dupuytren’s
contracture disability, in all of these jurisdictions.
In support of our current FDA
interaction, a leading pharmaceutical biosimilar manufacturer has agreed to participate with the Company in the FDA advice discussion
regarding manufacturing and safety of the proposed biosimilar for adalimumab. In addition, such manufacturer has indicated that it wishes
to supply the anti-TNF biosimilar drug to be used in the Phase 3 study; however, no definitive agreements with the supplier have been
entered into to date. It is expected that any agreements with such supplier would be conditional upon the outcome of the aforementioned
FDA discussions, and we may be unable to come to mutually agreeable definitive terms with such supplier.
The Company is
currently taking into consideration the guidance from the MHRA in its discussions with the FDA and planning the potential Phase 3 study
to be carried out, if necessary, provided that funding for such study is available.
Forward-Looking Statements
This Current Report on Form 8-K
includes “forward-looking statements”, including information about management’s view of the Company’s future expectations,
plans and prospects, within the safe harbor provisions provided under federal securities laws, including under The Private Securities
Litigation Reform Act of 1995 (the “Act”). Words such as “expect,” “estimate,” “project,”
“budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,”
“could,” “should,” “believes,” “predicts,” “potential,” “continue”
and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should
not rely on these forward-looking statements as predictions of future events.
These forward-looking statements
and factors that may cause such differences include, without limitation, risks regarding current negative operating cash flows and a need
for additional funding to finance our operating plans; the terms of any further financing, which may be highly dilutive and may include
onerous terms, increases in interest rates which may make borrowing more expensive and increased inflation which may negatively affect
costs, expenses and returns; the ability of the Company and a pharmaceutical biosimilar manufacturer to come to terms on such manufacturer’s
supply of a drug to be used in a planned Phase 3 study, the terms thereof and timing thereof; the timing, funding for, and outcome of
a planned Phase 3 study; our ability to commercialize our drug candidates, if proven successful for treatment in trials; the timing of,
outcome of, and results of, clinical trials; statements regarding the timing of a marketing authorization application (MAA) submission
to the UK Medicines and Healthcare products Regulatory Agency (MHRA) and a New Drug Application submission (NDA) to the U.S. Food and
Drug Administration (FDA), our ability to obtain approval and acceptance thereof, the willingness of the MHRA to review such MAA and the
FDA to review such NDA, and our ability to address outstanding comments and questions from the MHRA and FDA; statements about the ability
of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the uncertainties associated
with the clinical development and regulatory approval of 180 Life Sciences’ drug candidates, including potential delays in the enrollment
and completion of clinical trials, the costs thereof, closures of such trials prior to enrolling sufficient participants in connection
therewith, issues raised by the FDA, the MHRA and the European Medicines Agency (EMA); the ability of the Company to maintain and renew
licenses, the rights under certain situations of licensors to terminate licenses; the ability of the Company to persuade regulators that
chosen endpoints do not require further validation; timing and costs to complete required studies and trials, and timing to obtain governmental
approvals; the accuracy of simulations and the ability to reproduce the outcome of such simulations in real world trials; 180 Life Sciences’
reliance on third parties to conduct its clinical trials, enroll patients, and manufacture its preclinical and clinical drug supplies;
the ability to come to mutually agreeable terms with such third parties and partners, and the terms of such agreements; 180 Life Sciences’
ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside
the United States, that apply to its product development activities; the timing of filing, the timing of governmental review, and outcome
of, planned Investigational New Drug (IND) applications for drug candidates; statements relating to expectations regarding future agreements
relating to the supply of materials and license and commercialization of products; the availability and cost of materials required for
trials; the risk that initial drug results are not predictive of future results or will not be able to be replicated in clinical trials
or that such drugs selected for clinical development will not be successful; challenges and uncertainties inherent in product research
and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success;
the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval
process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; changing market and
economic conditions; changes to applicable laws and regulations, including global health care reforms; expectations with respect to future
performance, growth and anticipated acquisitions; the continued listing of the Company’s securities on The Nasdaq Stock Market,
including the fact that the Company is not currently in compliance with such continued listing requirements; the ability of the Company
to execute its plans to develop and market new drug products and the timing and costs of these development programs; estimates of the
size of the markets for the Company’s potential drug products; the outcome of current litigation involving the Company; potential
future litigation involving the Company or the validity or enforceability of the intellectual property of the Company; global economic
conditions; geopolitical events and regulatory changes; the expectations, development plans and anticipated timelines for the Company’s
drug candidates, pipeline and programs, including collaborations with third parties; access to additional financing, and the potential
lack of such financing; and the Company’s ability to raise funding in the future and the terms of such funding, and dilution caused
thereby; and the effect of rising interest rates and inflation, economic downturns and recessions, declines in economic activity or global
conflicts. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange
Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks, and including the Annual Report on Form 10-K
for the year ended December 31, 2022, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, and future SEC filings. These
reports and filings are available at www.sec.gov and are available for download, free of charge, soon after such reports are filed with
or furnished to the SEC, on the “Investors”, “SEC Filings”, “All SEC Filings” page of our website
at www.180lifesciences.com.
Readers are cautioned not to place
undue reliance upon any forward-looking statements, which speak only as of the date made, including the forward-looking statements included
in this press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance
or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake
or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change
in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as otherwise provided
by law.
The inclusion of any website
address in this Form 8-K is intended to be an inactive textual reference only and not an active hyperlink. The information contained in,
or that can be accessed through, such website is not part of or incorporated into this Form 8-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: October 18, 2023
|
180 LIFE SCIENCES CORP. |
|
|
|
By: |
/s/ James N. Woody, M.D., Ph.D. |
|
|
Name: |
James N. Woody, M.D., Ph.D. |
|
|
Title: |
Chief Executive Officer |
v3.23.3
Cover
|
Oct. 12, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Oct. 12, 2023
|
Entity File Number |
001-38105
|
Entity Registrant Name |
180 LIFE SCIENCES CORP.
|
Entity Central Index Key |
0001690080
|
Entity Tax Identification Number |
90-1890354
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
3000 El Camino Real
|
Entity Address, Address Line Two |
Bldg. 4
|
Entity Address, Address Line Three |
Suite 200
|
Entity Address, City or Town |
Palo Alto
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94306
|
City Area Code |
(650)
|
Local Phone Number |
507-0669
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
Common Stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Trading Symbol |
ATNF
|
Security Exchange Name |
NASDAQ
|
Warrants to purchase shares of Common Stock |
|
Title of 12(b) Security |
Warrants to purchase shares of Common Stock
|
Trading Symbol |
ATNFW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 3 such as an Office Park
+ References
+ Details
Name: |
dei_EntityAddressAddressLine3 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
180 Life Sciences (NASDAQ:ATNF)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
180 Life Sciences (NASDAQ:ATNF)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024